Publication: Modelling the neuropathology of lysosomal storage disorders through disease-specific human induced pluripotent stem cells
Issued Date
2019-07-15
Resource Type
ISSN
10902422
00144827
00144827
Other identifier(s)
2-s2.0-85065119549
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Experimental Cell Research. Vol.380, No.2 (2019), 216-233
Suggested Citation
Julianna Kobolák, Kinga Molnár, Eszter Varga, István Bock, Bálint Jezsó, Annamária Téglási, Shuling Zhou, Maria Lo Giudice, Marianne Hoogeveen-Westerveld, WWM Pim Pijnappel, Phetcharat Phanthong, Norbert Varga, Narisorn Kitiyanant, Kristine Freude, Hideyuki Nakanishi, Lajos László, Poul Hyttel, András Dinnyés Modelling the neuropathology of lysosomal storage disorders through disease-specific human induced pluripotent stem cells. Experimental Cell Research. Vol.380, No.2 (2019), 216-233. doi:10.1016/j.yexcr.2019.04.021 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/50127
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Modelling the neuropathology of lysosomal storage disorders through disease-specific human induced pluripotent stem cells
Author(s)
Abstract
© 2019 The Authors Mucopolysaccharidosis II (MPS II) is a lysosomal storage disorder (LSD), caused by iduronate 2-sulphatase (IDS) enzyme dysfunction. The neuropathology of the disease is not well understood, although the neural symptoms are currently incurable. MPS II-patient derived iPSC lines were established and differentiated to neuronal lineage. The disease phenotype was confirmed by IDS enzyme and glycosaminoglycan assay. MPS II neuronal precursor cells (NPCs) showed significantly decreased self-renewal capacity, while their cortical neuronal differentiation potential was not affected. Major structural alterations in the ER and Golgi complex, accumulation of storage vacuoles, and increased apoptosis were observed both at protein expression and ultrastructural level in the MPS II neuronal cells, which was more pronounced in GFAP + astrocytes, with increased LAMP2 expression but unchanged in their RAB7 compartment. Based on these finding we hypothesize that lysosomal membrane protein (LMP) carrier vesicles have an initiating role in the formation of storage vacuoles leading to impaired lysosomal function. In conclusion, a novel human MPS II disease model was established for the first time which recapitulates the in vitro neuropathology of the disorder, providing novel information on the disease mechanism which allows better understanding of further lysosomal storage disorders and facilitates drug testing and gene therapy approaches.